We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
-17.49%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$2.12B
AUM Growth
-$643M
Cap. Flow
-$73.8M
Cap. Flow %
-3.48%
Top 10 Hldgs %
32.59%
Holding
150
New
6
Increased
39
Reduced
39
Closed
17

Top Buys

Rank Stock Value
1
WCG
Wellcare Health Plans, Inc.
WCG
+$41.3M
2
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$26.2M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$13.8M
4
SGEN
Seagen Inc. Common Stock
SGEN
+$12.7M
5
RARE icon
Ultragenyx Pharmaceutical
RARE
+$12.3M

Top Sells

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$30.7M
2
MOH icon
Molina Healthcare
MOH
+$26.6M
3
ARNA
Arena Pharmaceuticals Inc
ARNA
+$17.3M
4
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$15.6M
5
ECYT
Endocyte, Inc. Common Stock
ECYT
+$15.1M

Sector Composition

Rank Sector Weight
1 Healthcare 88.36%
2 Consumer Staples 0.36%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RARX
51
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
$13.7M 0.64%
750,000
– –
HRTX icon
52
Heron Therapeutics
HRTX
$92.9M
$13.6M 0.64%
525,000
– –
XENT
53
DELISTED
Intersect ENT, Inc
XENT
$13.1M 0.62%
465,000
+5,000
+1% +$146K
AXGN icon
54
Axogen
AXGN
$2.5B
$12.3M 0.58%
603,970
+60,496
+11% +$1.89M
A icon
55
Agilent Technologies
A
$41.2B
$12.3M 0.58%
182,800
+18,700
+11% +$1.26M
EXEL icon
56
Exelixis
EXEL
$13.4B
$12.2M 0.58%
621,400
+26,400
+4% +$471K
ZBH icon
57
Zimmer Biomet
ZBH
$18.4B
$12.2M 0.58%
121,025
-110,725
-48% -$12.5M
CELG
58
DELISTED
Celgene Corp
CELG
$11.9M 0.56%
185,150
-175,250
-49% -$12.9M
BPMC
59
DELISTED
Blueprint Medicines
BPMC
$11.5M 0.54%
213,658
+13,658
+7% +$830K
SGEN
60
DELISTED
Seagen Inc. Common Stock
SGEN
$11.5M 0.54%
+202,500
New +$12.7M
INSM icon
61
Insmed
INSM
$28.6B
$11.2M 0.53%
850,000
-40,000
-4% -$638K
IMMU
62
DELISTED
Immunomedics Inc
IMMU
$11.1M 0.53%
780,000
+5,000
+0.6% +$99.3K
DVA icon
63
DaVita
DVA
$11.7B
$11.1M 0.52%
215,200
-193,300
-47% -$12.4M
BMRN icon
64
BioMarin Pharmaceuticals
BMRN
$12.4B
$11M 0.52%
129,000
+4,000
+3% +$381K
BOLD
65
DELISTED
Audentes Therapeutics, Inc
BOLD
$10.7M 0.5%
500,000
+74,975
+18% +$1.93M
ASMB icon
66
Assembly Biosciences
ASMB
$529M
$10.2M 0.48%
37,500
-3,333
-8% -$964K
QTTB icon
67
Q32 Bio
QTTB
$464M
$10.1M 0.47%
25,000
-1,111
-4% -$420K
GBT
68
DELISTED
Global Blood Therapeutics, Inc.
GBT
$10.1M 0.47%
245,000
+95,000
+63% +$3.56M
EPZM
69
DELISTED
Epizyme, Inc
EPZM
$9.9M 0.47%
1,607,500
+366,247
+30% +$2.8M
ACRS icon
70
Aclaris Therapeutics
ACRS
$869M
$9.82M 0.46%
1,329,400
+449,400
+51% +$4.63M
RIGL icon
71
Rigel Pharmaceuticals
RIGL
$750M
$9.66M 0.46%
420,000
+7,500
+2% +$212K
BHVN
72
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$9.62M 0.45%
260,000
– –
FOLD
73
DELISTED
Amicus Therapeutics
FOLD
$9.58M 0.45%
1,000,000
– –
PBYI icon
74
Puma Biotechnology
PBYI
$454M
$9.29M 0.44%
456,462
-31,138
-6% -$935K
TVTX icon
75
Travere Therapeutics
TVTX
$5.78B
$9.05M 0.43%
400,000
– –
1 2
3
4 5

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q4 2018 Portfolio in Review

As of Q4 2018, Rock Springs Capital Management held 150 positions worth $2.12B, down 23% from $2.76B the previous quarter. Its ten largest holdings account for 33% of the portfolio.

Rock Springs Capital Management withdrew a net $73.8M in Q4 2018, closing 17 positions and reducing 39 holdings. Its most notable exit was AbbVie, an estimated $30.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 88% of assets, down from 90% a quarter earlier, followed by Consumer Staples.

Against the trend, Rock Springs Capital Management opened a new position in Seagen Inc. Common Stock worth $11.5M.

  • Rock Springs Capital Management's largest Q4 2018 buy was Seagen Inc. Common Stock: 202,500 shares worth $11.5M.
  • Rock Springs Capital Management added most to Wellcare Health Plans, Inc. in Q4 2018, an estimated $41.3M increase.
  • Rock Springs Capital Management's biggest Q4 2018 reduction was Molina Healthcare, cutting an estimated $26.6M.
  • Rock Springs Capital Management fully exited AbbVie in Q4 2018, selling an estimated $30.7M.
  • Rock Springs Capital Management's ten largest holdings make up 33% of its $2.12B portfolio in Q4 2018.
  • Rock Springs Capital Management opened 6 new positions and closed 17 in Q4 2018.
  • Rock Springs Capital Management's portfolio value fell 23% quarter-over-quarter to $2.12B.

Based on Rock Springs Capital Management's 13F filing for Q4 2018, filed 14 Feb 2019.